ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
85,015
0,38%
Bitcoin
65 049,28
0,13%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Idorsia Ltd (0RQE)

  7. Idorsia Ltd (0RQE) Actualités

0RQE Idorsia Ltd

1,9775
0,00 (0,00%)
20 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Idorsia Ltd 0RQE London Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,9775 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,9775 1,9775
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/6/202411:00UKREGIdorsia holds its Annual General Meeting of Shareholders
03/6/202407:00UKREGNew data with daridorexant to be presented at SLEEP 2024
03/6/202407:00UKREGNew data with daridorexant to be presented at SLEEP 2024
31/5/202407:00UKREGData from the PRECISION study of aprocitentan to be..
31/5/202407:00UKREGData from the PRECISION study of aprocitentan to be..
23/5/202407:00UKREGIdorsia issues invitation to the 2024 Annual General Meeting..
23/5/202407:00UKREGIdorsia issues invitation to the 2024 Annual General Meeting..
21/5/202407:00UKREGIdorsia announces changes to Idorsia Executive Committee and..
21/5/202407:00UKREGIdorsia announces changes to Idorsia Executive Committee and..
21/5/202406:50UKREGIdorsia announces financial results for the first quarter..
21/5/202406:50UKREGIdorsia announces financial results for the first quarter..
21/5/202406:40UKREGIdorsia announces financial results for the full year of..
21/5/202406:40UKREGIdorsia announces financial results for the full year of..
14/5/202417:45UKREGInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial..
14/5/202417:45UKREGInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial..
06/5/202418:35UKREGBondholders approve amended terms of the 2024 convertible..
06/5/202418:35UKREGBondholders approve amended terms of the 2024 convertible..
01/5/202418:00UKREGIdorsia increases the consent fee in connection with the..
01/5/202418:00UKREGIdorsia increases the consent fee in connection with the..
26/4/202407:00UKREGJERAYGO (aprocitentan) recommended for approval in Europe..
26/4/202407:00UKREGJERAYGO (aprocitentan) recommended for approval in Europe..
23/4/202407:00UKREGIdorsia publishes an invitation to a bondholder meeting
23/4/202407:00UKREGIdorsia publishes an invitation to a bondholder meeting
17/4/202407:00UKREGIdorsia publishes a Financial Status required for an..
17/4/202407:00UKREGIdorsia publishes a Financial Status required for an..
11/4/202407:00UKREGIdorsia takes steps to address short-term liquidity needs
11/4/202407:00UKREGIdorsia takes steps to address short-term liquidity needs
22/3/202407:00UKREGIdorsia thanks Guy Braunstein for his years of service as he..
22/3/202407:00UKREGIdorsia thanks Guy Braunstein for his years of service as he..
20/3/202407:00UKREGUS FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) –..
20/3/202407:00UKREGUS FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) –..
18/3/202407:00UKREGIdorsia and Viatris successfully close the transaction for..
18/3/202407:00UKREGIdorsia and Viatris successfully close the transaction for..
28/2/202407:00UKREGIdorsia and Viatris enter into a significant global research..
28/2/202407:00UKREGIdorsia and Viatris enter into a significant global research..
10/1/202407:00GLOBEIdorsia presents at the J.P. Morgan Healthcare Conference –..
03/11/202322:30GLOBENew Phase 3 data with aprocitentan for patients with..
24/10/202307:00GLOBEIdorsia gibt Finanzergebnisse für die ersten neun Monate..
23/10/202307:00GLOBEIdorsia is committed to further the science of sleep with a..
17/10/202317:45GLOBEInvitation to Idorsia's Nine-Month 2023 Financial Reporting..
06/9/202307:00GLOBEIdorsia reacquires the world-wide rights to aprocitentan
25/7/202307:00GLOBEIdorsia gibt Finanzergebnisse für das erste Halbjahr 2023..
21/7/202307:00GLOBEIdorsia announces a cost reduction initiative to be..
20/7/202308:30GLOBEIdorsia sells its Asia Pacific (ex-China) operations –..
18/7/202317:45GLOBEInvitation to Idorsia's HY 2023 Financial Results webcast..
10/7/202307:00GLOBEIdorsia announces its insomnia medication, QUVIVIQ..
26/6/202317:45GLOBENew Phase 3 data with aprocitentan for patients with..
23/6/202317:45GLOBENew Phase 3 data with aprocitentan to be presented at the..

Dernières Valeurs Consultées

LSE
0RQE
Idorsia
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés